文献速递瓣膜外科

经导管主动脉瓣置换治疗已植入瓣膜的结构性衰败(TAVR-in-TAVR):系统综述

Transcatheter aortic valve replacement for structural degeneration of previously implanted transcatheter valves (TAVR-in-TAVR): a systematic review.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该系统综述纳入13项研究共160例因经导管瓣膜衰败行TAVR-in-TAVR的患者,平均年龄74.8±7.8岁,距首次TAVR平均58.1±23.4个月。主要适应证为单纯狭窄(38.4%)、反流(31.4%)、混合病变(29.5%)和瓣叶血栓(8.8%)。手术成功率86.8%,院内死亡率1.25%,结论认为TAVR-in-TAVR是高危患者治疗衰败经导管瓣膜的有效替代方案,但需进一步评估耐久性和血流动力学表现。

要点

  • TAVR-in-TAVR可用于高危患者衰败经导管瓣膜的治疗,手术成功率86.8%。
  • 院内死亡率1.25%,主要并发症包括大血管并发症和起搏器植入各8.7%。
  • 术后5.6%患者存在中度反流,5%患者残余跨瓣平均压差≥20 mmHg。

核心结论

  • TAVR-in-TAVR是高危患者衰败经导管瓣膜治疗中标准外科手术的有效替代方案。
  • 尽管结果令人鼓舞,仍需进一步研究评估第二枚TAVR瓣膜的耐久性和血流动力学性能。

研究设计与样本

  • 系统综述,检索公共医学数据库,纳入13项研究(1项多中心研究、3项病例系列、9项病例报告),共160例因经导管瓣膜衰败行TAVR-in-TAVR的患者。

主要发现

  • 患者平均年龄74.8±7.8岁,男性84例(52.8%),距首次TAVR平均时间58.1±23.4个月。
  • 主要适应证为单纯狭窄(38.4%,平均压差44.5±18.5 mmHg)、反流(31.4%)、混合狭窄与反流(29.5%)及瓣叶血栓(8.8%)。
  • 手术成功率86.8%,第二枚TAVR瓣膜位置异常4例(2.5%),院内死亡率1.25%(2/160)。
  • 术后超声心动图显示中度反流5.6%(9/160),残余跨瓣平均压差≥20 mmHg者5%。
  • 术后并发症包括大血管并发症(8.7%)、新起搏器植入(8.7%)、急性肾衰竭(3.7%)、卒中(0.6%)和冠状动脉阻塞(0.6%)。

临床怎么用

  • 对于高危患者衰败的经导管主动脉瓣,TAVR-in-TAVR可作为标准外科手术的替代治疗选择。
  • 术前应评估瓣膜衰败模式(狭窄、反流或混合)及距首次TAVR时间,以规划TAVR-in-TAVR策略。
  • 术后需监测残余反流和跨瓣压差,并警惕血管并发症、起搏器植入及冠状动脉阻塞等风险。

局限性

  • 纳入研究以病例报告和病例系列为主,证据等级有限。
  • 随访时间较短(平均6±5.6个月),无法充分评估第二枚瓣膜的长期耐久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcatheter aortic valve replacement (TAVR) represents a valid treatment for patients with aortic valve stenosis and high or intermediate surgical risk. However, biological transcatheter valves can also experience a structural degeneration after years, and a redo-TAVR procedure (TAVR-in-TAVR) can be a valid option. We revised the current available literature for indications, procedural and technical details and outcome on TAVR-in-TAVR procedures for degenerated TAVR valves. METHODS: A systematic search was conducted in the public medical database for scientific articles on TAVR-in-TAVR procedures for degenerated transcatheter valves. Data on demographics, indications, first and second transcatheter valve type and size, mortality, complications and follow-up were extracted and analysed. RESULTS: A total of 13 studies (1 multicentre, 3 case series, 9 case reports) were included in this review, with a total amount of 160 patients treated with TAVR-in-TAVR procedures for transcatheter valve failure. The mean age was 74.8 ± 7.8 with 84 males (52.8%). The mean elapsed time from the first TAVR procedure was 58.1 ± 23.4 months. Main indication for TAVR-in-TAVR was pure stenosis (38.4%, with mean gradient of 44.5 ± 18.5 mmHg), regurgitation (31.4%), mixed stenosis and regurgitation (29.5%) and leaflet thrombosis (8.8%). Procedural success rate was 86.8%, with second TAVR valve malposition occurred in 4 cases (2.5%). The hospital mortality rate was 1.25% (2/160). Post-procedural echocardiographic control showed moderate regurgitation in 5.6% of patients (9/160) and residual transvalvular mean gradient ≥20 mmHg in 5% of cases. Postoperative complications included major vascular complications (8.7%), new pacemaker implantation (8.7%), acute kidney failure (3.7%), stroke (0.6%) and coronary obstruction (0.6%). The mean follow-up time was 6 ± 5.6 months with 1 non-cardiovascular death reported. CONCLUSIONS: TAVR-in-TAVR represents a valid alternative to standard surgery for the treatment of degenerated transcatheter valves in high-risk patients. Despite these promising results, further studies are required to assess durability and haemodynamic performances of the second TAVR valve.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gallo M, Fovino LN, Blitzer D, et al. Transcatheter aortic valve replacement for structural degeneration of previously implanted transcatheter valves (TAVR-in-TAVR): a systematic review. Eur J Cardiothorac Surg. 2022. PMID: 34662376. doi:10.1093/ejcts/ezab443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。